Reduce issues with trial and error prescribing, and reduce adverse medication reactions with CNSDose.
Offer CNSDose in your clinicCNSDose expands medication guidance from leading antidepressant guidance to expanded guidance for Geriatrics, Primary Care, Neurology, Internal Medicine, Psychiatry and more.
Leading blood-brain-barrier knowledge
The blood-brain-barrier is a filtering system of the small blood vessels that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances.
CNSDose has a world-leading understanding of how genetics influence this system. More specifically, CNSDose has an advanced understanding of the genetics of the ABC transporter pumps.
CNSDose uses the key to the blood brain barrier to create the CNSDose report
We have the first positive clinical trial for antidepressant treatment. Evidence indicates our gene-guided treatment can double the likelihood of recovery. A review by the US Department of Veterans Affairs Health Administration said 'CNSDose (antidepressant guidance) has the most favorable preliminary findings' based on this trial.
Depression is commonly associated with chronic diseases. Individuals diagnosed with common chronic conditions such as heart disease, arthritis, pain disorders, and chronic lung disease are at increased risk for developing depression. Individuals diagnosed with depression, are at increased risk for developing chronic conditions such as heart disease and diabetes. CNSDose provides genetic guidance for the better management of these co-occurring chronic conditions.
https://www.thecarlatreport.com/podcast/a-genetic-test-that-didnt-fail/
An independent review of CNSDose by America’s #1 psychiatry podcast